FONT-SIZE Plus   Neg

Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ 50 Mg/day

Pfizer Inc. (PFE) announced new data on PRISTIQ (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder, or MDD, in adults, including a long-term relapse prevention study.

According to the company, these new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the treatment of MDD. Lastly, new data also provide information regarding the discontinuation of PRISTIQ 50 mg/day for the treatment of adults with MDD.

These new PRISTIQ 50 mg/day data focus on key factors - efficacy, safety, long-term use and discontinuation - that clinicians often consider when assessing antidepressants for the treatment of MDD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Flying is the passion for British aviatrix Tracey Curtis Taylor, and she is now on a solo flight to cross three continents and 23 countries in her own vintage open cockpit biplane. She has already crossed half of her journey from U.K. to Australia with a target to cover 13 thousand miles. Sony Computer Entertainment Inc. Wednesday revealed that its popular PlayStation4 computer entertainment system has achieved total sales of more than 30.2 million units worldwide in a period of two years. The PS4 system is currently available in 124 countries. Cement giant LafargeHolcim (HCMLY.PK, HCMLF.PK), formed by the combination of French Lafarge and Swiss peer Holcim, Wednesday said its sales declined for the third quarter as well as nine months.
comments powered by Disqus
Trade PFE now with 
Follow RTT